BioSpace News Archive

IVERIC bio, Inc. (Nasdaq: ISEE) announced today the appointment of Tony Gibney to Executive Vice President and Chief Business and Strategy Officer, effective December 13, 2021.

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, announced its 2022 corporate priorities and provided updated guidance.

A drug combination can safely prevent transplanted stem cells (graft) from attacking the recipient’s (host) body, allowing them to develop into healthy new blood and immune cells, a new study shows.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement in principle with the Australian Government to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Victoria, Australia including access to Moderna’s mRNA development engine.

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO),today reported new data from the ongoing long-term extension study assessing the duration of effects of mitapivat on hemoglobin response and transfusion burden reduction in adults with pyruvate kinase (PK) deficiency who had participated in one of the pivotal studies, ACTIVATE and ACTIVATE-T, conducted in not regularly transfused and regularly transfused adults with PK deficiency, respectively.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first presentation of Phase 2 data and updated Phase 1 data from the MajesTEC-1 study of teclistamab, an off-the-shelf T-cell investigational redirecting bispecific antibody, being studied for the treatment of patients with relapsed or refractory multiple myeloma.

Sierra Oncology, Inc. (NASDAQ: SRRA), today announced data from new retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate baseline ferritin differentially predicts Week 24 Transfusion Independence Response for momelotinib and ruxolitinib in patients with myelofibrosis.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), today announced the presentation of new preclinical data on vecabrutinib, a reversible inhibitor of Bruton’s tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK), in oral and poster presentations at the 2021 American Society of Hematology (ASH) Annual Meeting.

Samsung Biologics (207940.KS), the world’s leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN).

Global Gamma Delta Car T Cells Based Cancer immunotherapy Market To Surpass USD 4 Billion By 2026 Says Kuick Research.